PAG
PRTK

Private Advisor Group’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Private Advisor Group’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-500
Closed -$3K – 3654
2020
Q2 		$3K Buy
+500
New +$2.22K ﹤0.01% 3497

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Private Advisor Group's PRTK Position: Q3 2020 in Review

Private Advisor Group sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2020, closing a stake of 500 shares — an estimated $3K sold.

Private Advisor Group first reported a position in PRTK in Q2 2020 and held it in 1 quarter. The position peaked at $3K in Q2 2020. 100 funds tracked by Wall St. Rank hold PRTK as of Q3 2020.

  • Private Advisor Group reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Private Advisor Group sold 500 Paratek Pharmaceuticals, Inc. shares in Q3 2020, an estimated $3K.
  • Private Advisor Group first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2020 and held it in 1 quarter.
  • Private Advisor Group's Paratek Pharmaceuticals, Inc. position peaked at $3K in Q2 2020.
  • 100 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.